Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATHENA maintenance study of rucaparib and nivolumab in front-line ovarian cancer
jRCT2080224597Phase 3Completed
- Sponsor
- pharma&
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of rucaparib and nivolumab in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (5 arms), sponsored by pharma&. Started Mar 2019; status: completed.
02
Drugs
rucaparibnivolumab
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on jRCT2080224597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224597.